| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 1204.35% | HC Wainwright & Co. | → $21 | Reiterates | Buy → Buy |
| 09/15/2023 | 1204.35% | HC Wainwright & Co. | $19 → $21 | Maintains | Buy |
| 08/31/2023 | 1080.12% | HC Wainwright & Co. | → $19 | Reiterates | Buy → Buy |
| 05/25/2023 | 148.45% | Oppenheimer | → $4 | Reiterates | → Outperform |
| 02/23/2021 | 1080.12% | HC Wainwright & Co. | $22 → $19 | Maintains | Buy |
| 12/16/2020 | 1266.46% | HC Wainwright & Co. | $18 → $22 | Maintains | Buy |
What is the target price for BioLine Rx (BLRX)?
The latest price target for BioLine Rx (NASDAQ: BLRX) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $21.00 expecting BLRX to rise to within 12 months (a possible 1204.35% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioLine Rx (BLRX)?
The latest analyst rating for BioLine Rx (NASDAQ: BLRX) was provided by HC Wainwright & Co., and BioLine Rx reiterated their buy rating.
When is the next analyst rating going to be posted or updated for BioLine Rx (BLRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLine Rx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLine Rx was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating BioLine Rx (BLRX) correct?
While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a reiterated with a price target of $0.00 to $21.00. The current price BioLine Rx (BLRX) is trading at is $1.61, which is within the analyst's predicted range.